---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006909"
form_type: "8-K"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:28:05.855352+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q1 revenue $17.4M (+12% YoY); FDA clearance for adolescent MDD expands TAM by ~35%

## Summary
- Revenue $17.4M (+12% YoY); U.S. treatment session revenue $13.0M (+22% YoY) driven by higher utilization.
- Net loss $(7.9)M ($0.27/share) improved from $(10.5)M ($0.38/share) in Q1 2023; EBITDA $(6.3)M vs $(9.4)M.
- NeuroStar received FDA clearance as first-line adjunct TMS for adolescents (15-21) with MDD; total addressable market increased ~35%.
- Shipped 41 systems (vs 49 in Q1 2023); system revenue down 14% due to customer credit challenges and Change Health cyberattack.
- Q2 2024 revenue guidance $18-19M; FY2024 revenue $78-80M; operating expenses $80-84M.

## SEC filing metadata
- accession: 0001558370-24-006909
- form_type: 8-K
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/0001558370-24-006909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/stim-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006909
- JSON: https://secwatch.observer/filing/0001558370-24-006909.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006909.txt

## Key facts
- Earnings Releases
  Neuronetics, Inc. reported first quarter of 2024; three months ended March 31, 2024 results: revenue $17.4 million, net income $(7.9) million, or $(0.27) per share, EPS $(0.27) per share.
  - Period: first quarter of 2024; three months ended March 31, 2024
  - Revenue: $17.4 million
  - Net income: $(7.9) million, or $(0.27) per share
  - EPS: $(0.27) per share
  - Result: reported results
  source text: therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights ● First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023 ● U.S. treatment session revenue increased by 22% versus the first quarter of 2023 ● U.S. NeuroStar Advanced Therapy system
  evidence_url: https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/0001558370-24-006909-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.